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1 gene anomaly in the patient subset, suggest‑
ing that thrombophilia screening in ST cases 
may be justified.
Lastly, surgical revascularization may even 
be chosen initially to prevent failed PCI in such 
patients.
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Author’s reply I have read with great atten‑
tion the comment written by Güner et al to our 
article. The rate of stent thrombosis (ST) has 
been gradually reduced in the recent years by 
improving stent platforms, optimizing proce‑
dural techniques, and antiplatelet treatment. 
However, the problem has not been solved in 
its entirety. The rate of ST remains at the level 
To the editor We have recently read with great 
interest the article by Chyrchel et al1 entitled 
“Recurrent stent thrombosis in a patient with 
neurofibromatosis type 1.” We appreciate the au‑
thors for the successful treatment of recurrent 
stent thrombosis (ST) in a patient with neuro‑
fibromatosis type 1. On the other hand, we be‑
lieve that there are several major drawbacks that 
need to be addressed.
First of all, ST is a rare but fatal complica‑
tion following percutaneous coronary inter‑
ventions (PCI).2 Despite technological advanc‑
es in PCI, this complication is still associated 
with significant morbidity and mortality. Al‑
though the pathophysiology of ST is versatile, 
most STs depend on the mechanical factors as‑
sociated with the implanted stent (underexpan‑
sion, malapposition, edge ‑dissections, and re‑
sidual inflow ‑outflow disease). Hence, intravas‑
cular imaging has been instrumental in opti‑
mizing the technique of coronary stenting as 
currently practiced.3 The 2018 European So‑
ciety of Cariology / European Association for 
Cardio ‑Thoracic Surgery guidelines on myocar‑
dial revascularization recommend intravascu‑
lar imaging to prevent strut malapposition for 
PCI.3 We know that suboptimal stent expan‑
sion is the single most important factor which 
has most strongly been associated with ST af‑
ter PCI.4 The readers may wonder whether me‑
chanical factors of ST in a patient with recur‑
rent ST were excluded by intravascular imag‑
ing methods (intravascular ultrasound or op‑
tical coherence tomography).
Second, the effect of hereditary coagulation 
disorders in the formation of ST has been pre‑
viously evaluated in a limited number of studies. 
Specifically, G1691A Factor V Leiden, G20210A 
factor II mutation, and C677T homozygous 
methylenetetrahydrofolate reductase polymor‑
phism were evaluated in patients with ST.5 Al‑
though no statistically significant relationship 
was found between these gene variations and ST, 
there is a relatively high prevalence of at least 
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of 1% in patients with STEMI.1 Due to the high 
rate of fatal consequences of ST (death, cardio‑
genic shock), every scientific discussion and pro‑
posal which could further reduce the ST rate 
is justified.
The main purpose of the article was to empha‑
size the potential role of vascular and histolog‑
ical pathology associated with rare neurofibro‑
matosis disorders which could increase the risk 
of stent thrombosis independently of the well ‑
‑known risk factors.2 I could agree that advanced 
visualization techniques (intravascular ultra‑
sound, optical coherence tomography) should 
be considered to exclude mechanical causes of 
stent thrombosis in patients with acute coro‑
nary syndrome.3 On the other hand, technical 
faults of stent implantation: small diameter, 
stent underexpansion, incomplete stent struts 
apposition, or dissections are mostly responsi‑
ble for early ST within first hours or days after 
the procedure.4 In the presented case, the first 
ST occurred 3 years after the procedure and the 
second, 10 months after the procedure, which 
could point to another cause of ST.
Hereditary coagulation disorders and throm‑
botic factors insufficiency were investigated in 
relation to ST appearance in the recent years.5 
Coagulation disorders cannot be categorically 
excluded as a potential reason for stent throm‑
bosis. In our case, they would probably reveal 
themselves earlier in youth or after the first im‑
plantation of stents 4 years before the presented 
events. In our institution, we screen patients to‑
wards hereditary coagulation disorders in case of 
atypical localization of thrombosis or acute coro‑
nary syndrome appearing before 40 years of age.
In my opinion urgent coronary artery bypass 
grafting in this clinical situation was not a rea‑
sonable therapeutic option. Acute myocardial in‑
farction, aggressive antiplatelet and antithrom‑
botic treatment that significantly increases risk 
of major hemorrhagic complications during a 
cardiac surgery have made this option debatable. 
Besides 1‑vessel bypass grafting (except the left 
anterior descending artery) is very rarely per‑
formed in clinical practice even in stable patients.
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